Christopher J. Schultz, MD

Publications

• Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.

  (Hall WA, Paulson E, Li XA, Erickson B, Schultz C, Tree A, Awan M, Low DA, McDonald BA, Salzillo T, Glide-Hurst CK, Kishan AU, Fuller CD.) CA Cancer J Clin. 2022 01;72(1):34-56 PMID: 34792808 PMCID: PMC8985054 SCOPUS ID: 2-s2.0-85119184109 11/19/2021

• Characterization of Underrepresented Populations in Modern Era Clinical Trials Involving Radiation Therapy.

  (Bero EH, Rein LE, Banerjee A, Straza MW, Lawton CAF, Schultz CJ, Erickson BA, Siker ML, Hall WA.) Pract Radiat Oncol. 2021 Nov-Dec;11(6):453-459 PMID: 34742459 SCOPUS ID: 2-s2.0-85118502646 11/08/2021

• Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.

  (de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Daamen LA, Faivre-Finn C, Fuller CD, Goldwein J, Hafeez S, Hall E, Harrington KJ, van der Heide UA, Huddart RA, Intven MPW, Kirby AM, Lalondrelle S, McCann C, Minsky BD, Mook S, Nowee ME, Oelfke U, Orrling K, Philippens MEP, Sahgal A, Schultz CJ, Tersteeg RJHA, Tijssen RHN, Tree AC, van Triest B, Tseng CL, Hall WA, Verkooijen HM, MR-Linac Consortium.) Int J Radiat Oncol Biol Phys. 2021 11 15;111(4):867-875 PMID: 34265394 SCOPUS ID: 2-s2.0-85113219681 07/16/2021

• The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer.

  (Kish JA, Zhang Q, Langer CJ, Nguyen-T??n PF, Rosenthal DI, Weber RS, List MA, Wong SJ, Garden AS, Hu K, Trotti AM, Bonner JA, Jones CU, Yom SS, Thorstad W, Schultz CJ, Ridge JA, Shenouda G, Harris J, Le QT.) J Geriatr Oncol. 2021 07;12(6):937-944 PMID: 33814339 PMCID: PMC8829803 SCOPUS ID: 2-s2.0-85103725742 04/06/2021

• Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.

  (Awan MJ, Gittleman H, Barnholtz-Sloan J, Machtay M, Nguyen-Tan PF, Rosenthal DI, Schultz C, Huth BJ, Thorstad WL, Frank SJ, Kim H, Foote RL, Lango MN, Shenouda G, Suntharalingam M, Harris J, Zhang Q, Le QT, Yao M, NRG Oncology Group.) Oral Oncol. 2021 05;116:105241 PMID: 33640577 PMCID: PMC8144062 SCOPUS ID: 2-s2.0-85101423773 03/01/2021

• In Reply to Pe??agar?-cano.

  (Bovi JA, Schultz CJ.) Int J Radiat Oncol Biol Phys. 2021 02 01;109(2):641 PMID: 33422280 SCOPUS ID: 2-s2.0-85098481483 01/11/2021

• A closer look at 30 day hospital readmissions after head and neck cancer surgery

  (Puccia R, Ramamurthi A, Grond SE, McCormick C, Ng A, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz C, Wong S, Shreenivas A, Zenga J.) American Journal of Otolaryngology - Head and Neck Medicine and Surgery. 1 September 2021;42(5) SCOPUS ID: 2-s2.0-85108366965 09/01/2021

• BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.

  (Vassilakopoulou M, Won M, Curran WJ, Souhami L, Prados MD, Langer CJ, Rimm DL, Hanna JA, Neumeister VM, Melian E, Diaz AZ, Atkins JN, Komarnicky LT, Schultz CJ, Howard SP, Zhang P, Dicker AP, Knisely JPS.) Oncology. 2021;99(9):580-588 PMID: 33957633 PMCID: PMC8491475 SCOPUS ID: 2-s2.0-85107468485 05/07/2021

• Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813.

  (Fleming JL, Pugh S, Bell EH, Chang SM, McElroy J, Becker A, Timmers CD, Shih HA, Ashby L, Hunter GK, Bahary JP, Schultz CJ, Kavanagh BD, Yung WA, Robins I, Werner-Wasik M, Chakravarti A.) Int J Radiat Oncol Biol Phys. 2020 12 01;108(5):1399 PMID: 33427658 SCOPUS ID: 2-s2.0-85100069396 01/12/2021

• The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy.

  (de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Faivre-Finn C, Fuller CD, Goldwein J, Hafeez S, Hall E, Harrington KJ, van der Heide UA, Huddart RA, Intven MPW, Kirby AM, Lalondrelle S, McCann C, Minsky BD, Mook S, Nowee ME, Oelfke U, Orrling K, Sahgal A, Sarmiento JG, Schultz CJ, Tersteeg RJHA, Tijssen RHN, Tree AC, van Triest B, Hall WA, Verkooijen HM.) Front Oncol. 2020;10:1328 PMID: 33014774 PMCID: PMC7505056 10/06/2020

• Improving Structure Delineation for Radiation Therapy Planning Using Dual-Energy CT.

  (Noid G, Zhu J, Tai A, Mistry N, Schott D, Prah D, Paulson E, Schultz C, Li XA.) Front Oncol. 2020;10:1694 PMID: 32984048 PMCID: PMC7484725 09/29/2020

• The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy

  (de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Faivre-Finn C, Fuller CD, Goldwein J, Hafeez S, Hall E, Harrington KJ, van der Heide UA, Huddart RA, Intven MPW, Kirby AM, Lalondrelle S, McCann C, Minsky BD, Mook S, Nowee ME, Oelfke U, Orrling K, Sahgal A, Sarmiento JG, Schultz CJ, Tersteeg RJHA, Tijssen RHN, Tree AC, van Triest B, Hall WA, Verkooijen HM.) Frontiers in Oncology. 7 September 2020;10 SCOPUS ID: 2-s2.0-85091425211 09/07/2020